{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regorafenib+%28BAY73-4506%29", "query": { "intervention": "Regorafenib (BAY73-4506)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 94, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Regorafenib+%28BAY73-4506%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T01:26:46.264Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06087263", "title": "Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumors" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2024-06-18", "completion_date": "2034-07-01", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06087263" }, { "nct_id": "NCT03563157", "title": "QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer Metastatic", "mCRC" ], "interventions": [ { "name": "Aldoxorubicin Hydrochloride", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "ETBX-021", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" }, { "name": "GI-6207", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "SBRT", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2018-09-28", "completion_date": "2019-08-21", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03563157" }, { "nct_id": "NCT02368886", "title": "Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "Rectal Adenocarcinoma", "Stage III Colorectal Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7" ], "interventions": [ { "name": "Clobetasol Propionate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2015-03-27", "completion_date": "2023-03-02", "has_results": true, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "South Bend", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02368886" }, { "nct_id": "NCT04701476", "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer; Lung Cancer" ], "interventions": [ { "name": "TATE and pembrolizumab", "type": "DRUG" }, { "name": "TAS-102 pill", "type": "DRUG" }, { "name": "Regorafenib Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teclison Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2021-05-20", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04701476" }, { "nct_id": "NCT02466802", "title": "Study of Regorafenib and Sildenafil for Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "Sildenafil Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-07-01", "completion_date": "2019-01-28", "has_results": false, "last_update_posted_date": "2020-02-20", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02466802" }, { "nct_id": "NCT02119676", "title": "Study of Ruxolitinib in Colorectal Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CRC (Colorectal Cancer)" ], "interventions": [ { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2014-03", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 57, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Mesa, Arizona + 54 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02119676" }, { "nct_id": "NCT01853046", "title": "Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2013-06", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-02-20", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • St Louis, Missouri + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01853046" }, { "nct_id": "NCT03289273", "title": "Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Liver Neoplasms" ], "interventions": [ { "name": "Regorafenib (Stivarga, BAY73-4506)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1010, "start_date": "2017-09-13", "completion_date": "2022-06-21", "has_results": false, "last_update_posted_date": "2023-06-13", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 17, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03289273" }, { "nct_id": "NCT01068769", "title": "Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumor" ], "interventions": [ { "name": "regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Suzanne George, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2010-02", "completion_date": "2020-08", "has_results": true, "last_update_posted_date": "2020-08-24", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Portland, Oregon • Philadelphia, Pennsylvania", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01068769" }, { "nct_id": "NCT05425940", "title": "Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "XL092", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 901, "start_date": "2022-09-07", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-05T01:26:46.264Z", "location_count": 45, "location_summary": "Jonesboro, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more", "locations": [ { "city": "Jonesboro", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05425940" } ] }